Retatrutide and NAD+: Brief Overview
Retatrutide is an investigational triple agonist that engages the GIP, GLP-1, and glucagon receptors, developed by Eli Lilly and still in Phase 3 trials. It lowers appetite and raises fat-oxidation demand, largely through its glucagon arm.
NAD+ is a coenzyme present in every cell — the redox cofactor that beta-oxidation spends to turn mobilized fat into ATP.
Retatrutide and NAD+ are paired because retatrutide can mobilize fat faster than a depleted NAD+ pool burns it. When that happens, the user may still be in a deficit but feel flat, cold, foggy, restless, or underpowered. NAD+ support keeps the burn-to-ATP step from becoming the limiting factor, so appetite control and oxidation capacity move together.
No published trial has tested the combination directly. The rationale is mechanistic (beta-oxidation is NAD+-dependent) plus practitioner observation. Injectable NAD+ is not mandatory, and it does not directly accelerate weight loss; the point is metabolic capacity during a deep deficit.
| At a Glance | |
|---|---|
| Who it's for | Retatrutide users who want weight-loss without the energy crash |
| Duration | 12 weeks |
| Key components | Retatrutide (0.3–4 mg/week) + NAD+ (100–200 mg IM, 2–3×/week) |
| Results timeline | Appetite changes often appear early; body-composition changes follow |
| Difficulty | Beginner |
Protocol in Context
This is for retatrutide users who want:
- Clear structure with minimal complexity
- Appetite control without energy collapse
- A foundation for more advanced protocols later
- A conservative starting point before adding MOTS-c, L-Carnitine, or GH-axis support
The goal is not aggressive weight loss at the expense of training output, sleep, or lean-mass protection. It is a clean metabolic base: lower appetite, better glucose control, and enough redox capacity to use the fuel being released.
NAD+ Supports Retatrutide Driven Weight-Loss
Retatrutide drives fast weight loss, and burning that much stored fat for fuel leans hard on the cell's energy machinery. When that machinery runs short on the fuel it needs to keep up (NAD+), users hit the wall many report a few months in — weight loss stalls and energy crashes. Keeping NAD+ supplied helps hold that plateau off: it's a capacity layer for the deficit retatrutide creates, not a weight-loss accelerator.
Retatrutide¹ (LY3437943, developed by Eli Lilly) is a triple agonist that engages three receptors — GIP, GLP-1, and glucagon — at very different fractions across the dose range:
| Dose | GIPR (obese / lean) | GLP-1R (obese / lean) | GCGR (obese / lean) |
|---|---|---|---|
| 0.3 mg | 21% / 27% | 2.2% / 3.0% | 0.30% / 0.41% |
| 0.5 mg | 31% / 38% | 3.6% / 4.9% | 0.50% / 0.68% |
| 1 mg | 48% / 55% | 7.0% / 9.3% | 1.00% / 1.35% |
| 2 mg | 65% / 71% | 13% / 17% | 1.98% / 2.66% |
| 4 mg | 78% / 83% | 23% / 29% | 3.88% / 5.19% |
| 8 mg | 88% / 91% | 38% / 45% | 7.46% / 9.86% |
| 12 mg | 92% / 94% | 47% / 55% | 10.79% / 14.10% |
Numbers are receptor engagement percentages — the fraction of each receptor type bound and signaling at chronic steady state. Obese column anchored at the Jastreboff Phase 2 cohort (~109 kg, BMI 37); lean column at ~75 kg metabolically healthy.
Two patterns matter for the dose decision.
First, GIPR engages fast. By 1 mg, the GIP receptor is already in the working range — held continuously every hour of every week, instead of in the brief meal-time pulses native physiology produces. That's the receptor doing the direct fat-cell work (insulin efficiency, adipose thermogenesis), and it is mostly online before the appetite arm (GLP-1R) has climbed. Even at 1 mg, retatrutide is a GIP-dominant drug; the GLP-1 arm is softer than pure GLP-1 agonists, and the glucagon arm climbs proportionally with dose.
Second, the lean and obese columns sit close. The per-mg exposure shift between phenotypes is real but modest. The larger phenotype difference is downstream: the same engagement produces a measurably stronger cardiovascular response in lean cohorts — higher resting heart-rate sensitivity, sharper β-OHB rise, faster onset of skin sensitivity and chills. Lean, sensitive, South Asian, or tirzepatide-transition users typically start at 0.3–1 mg with 4+ week holds, not because the receptor engagement is different at the same dose, but because the body responds more loudly to the same engagement.
Glucagon-mediated effects are threshold-dependent. At lower doses the signal is more liver-facing: hepatic fat handling, glucose output, and energy-expenditure pressure. As exposure rises, glucagon-driven peripheral effects emerge: resting heart-rate elevation, chills, insomnia, and a more catabolic feel. Skin sensitivity (dysesthesia) climbs with dose too, but it rides the GLP-1 arm rather than glucagon.
The dose decision is therefore not just "how much weight loss." It is how quickly the user pushes GIP, GLP-1, and glucagon engagement at once.
But mobilized fat still needs to be burned. That's where NAD+ becomes essential.
In a deficit, cells lean heavily on β-oxidation—the pathway that converts fat to ATP. This pathway spends NAD+ every cycle.² When demand outruns availability or recycling, fat can be mobilized faster than it is comfortably converted to usable energy.³ Fatigue sets in, cravings return, and progress stalls.
Retatrutide makes this more acute than other GLP-1 drugs. Its glucagon receptor activation increases fat oxidation specifically in the liver — which is also a major hub for NAD+ recycling and the canonical site for nicotinamide clearance. That concentrates fat-oxidation demand on an organ that already runs heavy NAD+ traffic. The math is tighter with retatrutide because the glucagon arm concentrates demand on hepatic NAD+ recycling — load that other GLP-1-class drugs distribute differently.
Maintaining NAD+ keeps the fat-burn → ATP chain from becoming the weak link. The target is not stronger appetite suppression. The target is better tolerance of the deficit retatrutide already created.
Preventing the Reta Driven Metabolic Wall
A subset of GLP-1 users hit a "wall" around months 3-6: energy crashes, exercise tolerance drops, progress feels stuck. The mechanism below is real and fairly well understood, but it does not hit everyone equally. It concentrates in users who start with a vulnerability: marginal thyroid, subclinical mitochondrial dysfunction, a prior chronic-fatigue history, a micronutrient-thin diet, or disrupted sleep. Most users never hit the wall; the ones who do tend to carry one of those.
Retatrutide mobilizes stored fat through its triple-receptor mechanism. That fat still has to be converted to ATP through beta-oxidation, the pathway that breaks fat into usable energy. Every turn of beta-oxidation hands electrons to NAD+, converting it to NADH; the cell then regenerates NAD+ by passing those electrons down the electron transport chain at Complex I. What limits the cycle is not only the size of the NAD+ pool but the ratio of NAD+ to NADH: there has to be oxidized NAD+ free to accept the next round of electrons.⁸
The ratio spiral:
- Caloric deficit raises fat-oxidation demand; beta-oxidation runs at high capacity
- The same deficit lowers T3, which slows the Complex I step that regenerates NAD+ from NADH⁸
- NADH builds up faster than it clears, and the NAD+/NADH ratio falls
- The low ratio quiets sirtuins and mimics a low-oxygen state in normal oxygen, a "pseudohypoxic" pattern⁸
- Fat is mobilized but not cleanly converted to ATP: the wired-but-underpowered feeling, and progress stalls
Competing demands for NAD+
The NAD+ pool serves four masters simultaneously—and they all compete for the same finite resource:
| System | What It Does | Demand During Retatrutide |
|---|---|---|
| Energy production | Converts fat to ATP | Running overtime |
| DNA repair | Fixes metabolic stress damage | Increases under caloric deficit |
| Sirtuin activation | Stress adaptation and longevity | Competes with energy |
| Inflammation control | CD38-mediated immune signaling | May spike during weight loss |
When energy production dominates the pool—as it does during aggressive metabolic protocols—the other systems get rationed. Recovery slows, stress adaptation weakens, and the "wall" materializes.
Maintaining the NAD+ floor
NAD+ support keeps all four systems from competing against a shrinking floor:
- Energy production runs without exhausting other pathways
- DNA repair continues in the background
- Sirtuin-driven adaptation stays active
- The depletion spiral never gains momentum
This is the logic behind the combination: retatrutide creates the deficit and mobilizes fat; NAD+ helps preserve the capacity to oxidize it. The biochemistry here is established: beta-oxidation requires NAD+. One nuance matters. Because the bottleneck is the NAD+/NADH ratio, supplying NAD+ helps most when the clearance side (Complex I throughput) is intact; where mitochondrial throughput is itself impaired, refilling the pool alone can push the ratio the wrong way, and the next layer is the mito-stack (SS-31 to restore Complex I) rather than more NAD+.⁸ What has not been tested in a controlled trial is whether supplementing NAD+ during GLP-1 therapy specifically prevents the fatigue wall. The mechanistic case is strong; the clinical proof is still emerging.
For deeper understanding of NAD+ mechanisms, including the CD38/senescent cell loop that drives age-related depletion, see the complete NAD+ guide.
What NAD+ support is not
NAD+ is not a weight loss accelerator. It does not make retatrutide more potent at the receptor. It is a capacity layer: useful when the metabolic machinery needs to handle higher throughput without running into fatigue, poor recovery, or compensatory cravings.
Dosing
Retatrutide 0.3–4mg total weekly depending on starting weight and metabolic health, each dose held 4+ weeks before titration. NAD+ 50–100 mg every other day or 100–200 mg 2–3×/week; IM preferred, SubQ acceptable at lower/split doses. Oral NR 300–500 mg or NMN 250–500 mg daily as the maintenance layer.
| Parameter | Retatrutide | NAD+ |
|---|---|---|
| Dose | 0.3–4 mg total weekly | 50–100 mg (EoD) or 100–200 mg (2–3× weekly) |
| Frequency | Once weekly injection | Every other day, or 2–3× per week |
| Timing | Same day each week | Morning or mid-day |
| Route | Subcutaneous injection | IM preferred; SubQ acceptable |
| Note | Each dose holds 4+ weeks before any titration | First-phase loading for users with a depleted baseline |
The peptide reconstitution calculator determines your exact injection volume based on reconstitution concentration. For preparation instructions, see the reconstitution guide.
The injectable NAD+ range above is a loading-phase convention. It applies when there is reason to expect a depleted baseline — age 50+, recovering from chronic illness or a post-viral state, prolonged caloric deficit, chronic stress, or symptomatic fatigue at protocol start. After 4-8 weeks of loading, the dose typically steps down to 2× weekly or transitions to oral precursors for ongoing support. Users without depletion markers can skip the loading phase and operate on oral precursors from the start.
The non-injectable route. Oral precursors — nicotinamide riboside (NR) at 300–500 mg daily or nicotinamide mononucleotide (NMN) at 250–500 mg daily — raise NAD+ levels more gradually than injections. NR has the cleaner human pharmacokinetic evidence base; NMN remains a reasonable oral option. They are not the same as injectable NAD+, but they are legitimate maintenance support. See the NAD+ guide for a full comparison of repletion strategies.
Weekly Schedule (Example)
| Compound | Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|---|
| Retatrutide | — | — | 0.3–4 mg | — | — | — | — |
| NAD+ | 50–200 mg | — | 50–200 mg | — | 50–200 mg | Rest | Rest |
The pattern flexes to whatever retatrutide frequency the schedule runs on. Consistency matters more than the specific day.
Timeline: What to Expect
Weeks 1–4
- Adaptation — Appetite suppression begins within 48–72 hours
- Early signals — Reduced snacking, flatter glucose curves, 2–4 lb loss (some water/glycogen)
- Side effects — Mild nausea possible; smaller protein-first meals help
- Energy — May fluctuate initially; NAD+ is used to support the oxidation side of the deficit
Weeks 5–8
- Steady progress — Fat loss stabilizes at 1–2 lb/week
- Appetite — Becomes mechanical rather than emotional
- Energy — Often steadier when NAD+ support, protein, hydration, and sleep are all in place
- Challenge — May need reminders to eat enough protein
Weeks 9–12
- Consolidation — Scale progress may slow; body composition keeps improving
- Measurements — Waist circumference drops, clothes fit differently
- Metabolic state — Hunger control consistent for most users, energy stable
- Decision point — Continue, maintain, or advance to Intermediate
Lifestyle Foundation
This protocol works on top of, not instead of, basic metabolic hygiene.
| Component | Target |
|---|---|
| Protein | At least 1.6 g/kg body weight daily, 3-4 meals |
| Training | 2–4 resistance sessions/week |
| Movement | Walking on non-lift days (7–10k steps) |
| Cardio | Zone 2 (conversational pace) while adapting |
| Sleep | 7–9 hours; NAD+ often improves sleep via calmer glucose |
| Hydration | 3+ liters daily; retatrutide can blunt thirst signals |
When Progress Stalls
Dose escalation runs gradual and methodical in this protocol. When weight loss plateaus, the order of checks runs:
- Protein, steps, hydration, electrolytes, and the carbohydrate floor come first. A plateau with fatigue is often under-fueling, not a retatrutide-dose problem.
- Active nausea, constipation, resting heart rate, chills, skin sensitivity, insomnia, or appetite collapse marks a body that has not caught up to the current dose — the signal against a step up.
- A dose that has been quiet for 4+ weeks is the point where a small step beats jumping dose bands.
- When fatigue is the main limiter, the NAD+ lever moves first — toward 250 mg per dose, better route or dilution, or a steady NR/NMN base — before retatrutide climbs.
- The new pattern holds 4+ weeks before any further titration.
Managing Side Effects
| Issue | Primary Mitigation | Secondary Options |
|---|---|---|
| Nausea | Holding the dose; smaller protein-first meals | Injection timed away from the largest meal |
| Constipation | Fiber + fluids | Magnesium citrate at bedtime |
| Headache | Hydration | Added electrolytes |
| Resting HR increase | Holding the retatrutide dose | A step back when sustained or sleep-disrupting |
| Chills/skin sensitivity | Holding the retatrutide dose | No escalation until quiet |
| NAD+ injection sting | Slow push; diluted or split volume | IM rather than SubQ where appropriate |
| Fatigue | More NAD+ support, protein, carbs, sleep | Thyroid markers checked when cold/fatigued |
Monitoring
| Timepoint | What to Track |
|---|---|
| Baseline | Fasting glucose, fasting insulin, HbA1c, lipid panel, blood pressure, resting heart rate |
| Weekly | Weight, waist, energy, hunger, resting HR, sleep quality |
| Bi-weekly | Progress photos (front/side/back), clothing fit |
| Week 8–12 | Repeat baseline labs; watch glucose, insulin, TG/HDL ratio, blood pressure |
What Comes Next
After 12 weeks, two paths:
Maintenance: retatrutide drops to the lowest effective dose, often 0.5–2 mg/week. NAD+ can move to 100–150 mg weekly or 2×/week during training blocks, high stress, or fatigue-prone periods. Oral NR/NMN carries the daily maintenance layer.
Progress to Intermediate: the next layer adds L-Carnitine and MOTS-c for fat-oxidation capacity, with Tesamorelin in reach where lean-mass preservation or visceral-fat focus becomes central. See Retatrutide Recomp Protocol.
Contraindications
Retatrutide:
- Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- Active pancreatitis
- Pregnancy or breastfeeding
- Severe GI motility disorders
- Pre-existing atrial fibrillation, structural heart disease, or sustained tachycardia without medical oversight
NAD+ supplementation:
- Active cancer (NAD+ supports cellular metabolism broadly—it is not selective for healthy cells)
- Severe hepatic or renal impairment
- Concurrent chemotherapy (some regimens work by depleting NAD+; supplementation may interfere)
- Heart failure, significant arrhythmia, or recent cardiac events — injectable or IV NAD+ can stress the cardiovascular system; use medical oversight or oral NR/NMN instead
A history of cancer, gallbladder disease, or diabetic retinopathy, and concurrent glucose-lowering medications or anticoagulants that may need adjustment, are the profiles that warrant clinical oversight before starting.
Retatrutide Clinical Trial Results
Retatrutide has produced unusually large weight-loss outcomes in clinical trials. The landmark NEJM 2023 study (Jastreboff et al.) reported:
| Dose Level | Weight Loss at 48 Weeks |
|---|---|
| 1 mg weekly | −8.7% body weight |
| 4 mg weekly | −17.1% body weight |
| 8 mg weekly | −22.8% body weight |
| 12 mg weekly | −24.2% body weight |
Reading the arms. 1 mg is the real low-dose Phase 2 arm in non-diabetic obesity; 4 mg is mid-range, where glucagon thresholds begin to matter; 8 mg captures most of the 12 mg effect; 12 mg is the top of the Phase 2 range, with a higher side-effect burden.
The 1 mg arm matters because of where it lands on the receptor map. At 1 mg, retatrutide's GIP receptor engagement is already in the working range — held continuously every hour of every week, instead of in the brief meal-time pulses native physiology produces. The 8.7% weight loss reflects that engagement. It is not a tolerance-calibration step. No other compound in the GLP-1 family has direct sub-label-floor evidence at this magnitude.
The placebo-adjusted dose-response saturates between 8 and 12 mg. Beyond 8 mg, the additional weight loss is small relative to the side-effect cost. This beginner protocol uses conservative doses (0.3–4 mg weekly) to prioritize tolerability while still producing meaningful appetite and metabolic effects. The outcome depends heavily on starting weight, metabolic health, dose discipline, protein intake, and training.
Current Status & Availability
As of May 2026, retatrutide (development code: LY3437943) is not FDA approved. The first Phase 3 readout (TRIUMPH-4, reported December 11, 2025) showed an average 28.7% weight loss at 12 mg over 68 weeks — approximately 71 lb at the cohort's starting weight.⁷ Seven additional Phase 3 trials across the TRIUMPH registrational program⁶ are reading out through 2026.
Key regulatory milestones:
- Phase 2 results published in NEJM (2023)
- Phase 3 TRIUMPH-4 topline results reported December 11, 2025 (28.7% mean weight loss at 12 mg / 68 weeks, approximately 71 lb at cohort starting weight);⁷ additional trials reading out 2026 (NCT05929066, NCT06070792)
- FDA approval window: still pending the full Phase 3 package and regulatory review
Current non-trial access is research or grey-market, not an approved prescription pathway.
FAQ
What is the best retatrutide starting dose for beginners?
The standard starting dose is 1 mg per week by subcutaneous injection — the lowest arm directly measured in the Phase 2 obesity trial. Lean, sensitive, South Asian, bodybuilding-cut, or tirzepatide-transition users typically belong closer to 0.5 mg; further down at 0.3 mg for the lean South Asian phenotype with high cardiac sensitivity. Each dose holds at least 4 weeks before the next step, and active nausea, constipation, resting-HR elevation, chills, skin sensitivity, insomnia, or appetite collapse marks a body not yet caught up to the current dose — the signal against titrating through it. See the retatrutide dosing calculator for the full ladder.
How much weight can you lose on retatrutide?
Phase 2 means at 48 weeks (non-diabetic obesity):
| Dose | Mean weight loss |
|---|---|
| 1 mg | −8.7% |
| 4 mg | −17.1% |
| 8 mg | −22.8% |
| 12 mg | −24.2% |
Phase 3 TRIUMPH-4 (68 weeks, obesity + osteoarthritis cohort): 28.7% mean at 12 mg.⁷
These are averages, not ceilings. Trial responder distributions show meaningful spread — about 1 in 5 participants on the 12 mg arm in Phase 2 lost ≥30%; some lost much less. A 12-week beginner protocol using 0.3–4 mg is a different exposure window than the 48- or 68-week trials. Early losses often include water and glycogen; sustained fat loss depends on starting weight, metabolic health, dose discipline, protein intake, and training.
How does retatrutide compare to semaglutide (Ozempic)?
Retatrutide is a triple agonist; semaglutide is GLP-1-only. The pharmacology gap is wider than the receptor count suggests. Retatrutide's GLP-1 arm is intentionally softer than semaglutide's, which is why nausea profiles diverge at matched weight loss. Its GIP arm — absent in semaglutide entirely — engages adipose thermogenesis directly. Its glucagon arm actively mobilizes liver fat, while semaglutide reduces liver fat passively as a downstream consequence of weight loss. The structural difference shows up most clearly at sub-trial-floor doses: at 1 mg, retatrutide's GIP and GLP-1 arms are both already in the working range, and the glucagon arm has no analog in semaglutide at any dose.
Is retatrutide FDA approved?
As of May 2026, retatrutide is not FDA approved. The first Phase 3 data (TRIUMPH-4, reported December 11, 2025) showed 28.7% mean weight loss at 12 mg over 68 weeks — approximately 71 lb at the cohort's starting weight.⁷ Additional Phase 3 trials are reading out through 2026, and any approval depends on the full Phase 3 package and regulatory review. Current non-trial access is research or grey-market, not an approved prescription pathway.
Why combine retatrutide with NAD+?
NAD+ supports the beta-oxidation pathway that converts mobilized fat into ATP. When retatrutide creates a deficit, stored fat still has to be burned efficiently. During significant caloric restriction, training, or rapid weight loss, NAD+ demand can rise faster than recycling keeps up. Injectable NAD+ is usually dosed 100–250 mg IM 2–3×/week for active support; SubQ can work at lower or split doses if irritation is managed.
Can I use oral NMN or NR instead of injecting NAD+?
Yes. Oral precursors—nicotinamide riboside (NR, 300–500 mg daily) or nicotinamide mononucleotide (NMN, 250–500 mg daily)—raise NAD+ levels more gradually than injections but provide reliable baseline support. NR has more completed human trials; NMN has a growing evidence base. No definitive head-to-head human study exists between them. Injectable NAD+ is better suited for acute, high-demand support; oral precursors work well as a maintenance layer, especially for users who prefer not to inject. See the NAD+ guide for a detailed comparison.
How long does it take for retatrutide to work?
Appetite suppression often begins within 48–72 hours of the first injection as the GIP and GLP-1 pathways engage. Measurable weight change in the first 4 weeks often includes water and glycogen. The 12-week window is a practical evaluation block: long enough to assess appetite control, energy, training output, side effects, and whether the current dose is doing enough.
Limitations
The mechanistic case for combining NAD+ with retatrutide is sound: beta-oxidation requires NAD+, retatrutide increases beta-oxidation, therefore NAD+ demand rises. This logic follows established biochemistry.
What remains unproven is whether NAD+ supplementation specifically prevents or reverses the fatigue wall that GLP-1 users experience. No controlled trial has tested this directly. Individual response varies—some users on GLP-1s never hit a wall; some hit it regardless of supplementation.
The NAD+ decline data (50–80% by age 60) comes from observational studies. Clinical trials of NAD+ precursors typically run 8–12 weeks. Blood NAD+ does not always reflect tissue-level changes. Long-term outcomes from chronic NAD+ supplementation remain an open question.
This protocol is built on mechanistic evidence and practical experience. It is not a controlled clinical protocol, and it should not be treated as proof that NAD+ is required for every retatrutide user.
Related Topics
- Retatrutide Guide — complete retatrutide overview
- Retatrutide Dosing Calculator — reconstitution math for 10/12/24mg vials
- Retatrutide vs. Tirzepatide — head-to-head mechanism and weight-loss differential
- Retatrutide Recomp Protocol — advanced dual-axis protocol
- GLP-1 Hub — broader GLP-1 family coverage
- Why GLP-1 Medications Make You Tired — broader GLP-1 fatigue guide covering all compounds
- GLP-1 Compounds Tool — interactive comparison with trial data on weight loss and body composition
- NAD+ Guide — why NAD+ matters for metabolic function
- MOTS-c Guide — Next-level addition: MOTS-c for fat oxidation capacity
- Mito Stack — full SS-31 + MOTS-c + NAD+ stack for comprehensive mitochondrial support during GLP-1 protocols
References
¹ Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM 2023. NEJM 2023 retatrutide trial
² Yoshino J, et al. NAD+ Intermediates: The Biology and Therapeutic Potential. Cell Metabolism 2021. NAD+ intermediates: The biology and therapeutic potential
³ Covarrubias AJ, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology 2020.
⁴ Covarrubias AJ, et al. Senescent cells promote tissue NAD+ decline during ageing. Nature Metabolism 2020. Senescent cells promote tissue NAD+ decline with ageing
⁵ Camacho-Pereira J, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction. Cell Metabolism 2016.
⁶ Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea, and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. Published online October 15, 2025: 10.1111/dom.70209 — TRIUMPH Phase 3 program design (four trials, ~5,800 participants). TRIUMPH-4 is NCT05931367.
⁷ Eli Lilly press release, December 11, 2025. "Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis in first successful Phase 3 trial." investor.lilly.com — primary announcement of TRIUMPH-4 topline results. The 28.7% mean weight-loss figure at 12mg is consistent with the Lilly-announced 71.2 lb absolute figure at typical cohort starting weight.
⁸ NAD+/NADH ratio and pseudohypoxia — Gomes AP, et al. "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell 2013;155:1624-1638 (Sinclair lab). What gates the catabolic cycle is the NAD+/NADH ratio, not pool size alone: a falling ratio suppresses sirtuin activity and stabilizes HIF-1α, mimicking hypoxia in normal oxygen. Regenerating NAD+ from NADH depends on Complex I throughput, which caloric-deficit-driven T3 suppression slows. Where Complex I is the limiting step, supplying NAD+ alone can worsen the ratio — the rationale for pairing precursors with mitochondrial-membrane support (SS-31) rather than escalating NAD+ dose. DOI: 10.1016/j.cell.2013.11.037
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.